Effects of diethylstilbestrol (DES) medication during pregnancy: report from a symposium at the 10th international congress of ISPOG.
This article is a report based on presentations at the symposium Effects of Diethylstilbestrol (DES) Medication during Pregnancy at the conference Reproductive Life, 10th International Congress of The International Society of Psychosomatic Obstetrics and Gynaecology (ISPOG) in Stockholm, Sweden June 14-17, 1992. The objective of this symposium, chaired by Eylard van Hall and Ingar Palmlund, was to provide the basis for a discussion of how the risks of DES had been evaluated in different countries. In the general discussion following the presentations everybody present expressed concerns that DES might still be given to pregnant women in many parts of the world, called for measures to alert medical professionals world-wide to the hazards of the use of DES, and requested measures to effect an international ban of DES in medication for pregnant women.
Palmlund
I
I
Department of International Health Care Research (IHCAR), Karolinska Institutet, Stockholm, Sweden.
Apfel
R
R
Buitendijk
S
S
Cabau
A
A
Forsberg
J G
JG
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology; D000230:Adenocarcinoma / Q000139:chemically induced / Q000453:epidemiology; D003906:Developing Countries; D004054:Diethylstilbestrol / Q000009:adverse effects*; D004363:Drug Utilization; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data / Q000639:trends; D011247:Pregnancy / Q000187:drug effects*; D011248:Pregnancy Complications / Q000139:chemically induced / Q000453:epidemiology; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced / Q000453:epidemiology
D004054:Diethylstilbestrol